Compare · NVO vs SPRY
NVO vs SPRY
Side-by-side comparison of Novo Nordisk A/S (NVO) and ARS Pharmaceuticals Inc. (SPRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SPRY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 320.5x SPRY ($695.1M).
- Over the past year, NVO is down 21.8% and SPRY is down 61.0% - NVO leads by 39.3 points.
- SPRY has been more active in the news (16 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for SPRY).
- Company
- Novo Nordisk A/S
- ARS Pharmaceuticals Inc.
- Price
- $50.31-2.25%
- $6.99-6.24%
- Market cap
- $222.81B
- $695.1M
- 1M return
- +15.47%
- -27.94%
- 1Y return
- -21.78%
- -61.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 16
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SPRY
- SEC Form 8-K filed by ARS Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ARS Pharmaceuticals Inc.
- SEC Form 8-K filed by ARS Pharmaceuticals Inc.
- ARS Pharmaceuticals Announces CEO Succession
- SEC Form 4 filed by President Casale Donn
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Dadoo Rajeev
- SEC Form 4 filed by Director Shah Pratik
- SEC Form 4 filed by Director Kelly Michael
- SEC Form 4 filed by Director Schneider Phillip M